Literature DB >> 7780315

Tuberculosis in the 1990s. Issues for primary care physicians.

J M Fitzgerald1.   

Abstract

After declining for many years, tuberculosis rates have begun to level off in Canada. Groups at particularly high risk include aboriginal Canadians, immigrants from high-prevalence countries, HIV-infected people, and elderly men. If disease is suspected, appropriate investigations, including sputum tests for bacteriology and chest x-ray examinations, should be done. Response to treatment is excellent. Chemoprophylaxis is recommended for certain patients. Vaccination with BCG has a limited but important role, especially for aboriginal Canadians.

Entities:  

Mesh:

Year:  1995        PMID: 7780315      PMCID: PMC2146578     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  27 in total

1.  Recent trends in tuberculosis incidence in Canada 1980-90.

Authors:  A Brancker; E Ellis
Journal:  Can Commun Dis Rep       Date:  1992-09-11

2.  Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients.

Authors:  S W Dooley; M E Villarino; M Lawrence; L Salinas; S Amil; J V Rullan; W R Jarvis; A B Bloch; G M Cauthen
Journal:  JAMA       Date:  1992-05-20       Impact factor: 56.272

3.  A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects.

Authors:  F E Simons; J L McMillan; K J Simons
Journal:  J Allergy Clin Immunol       Date:  1990-10       Impact factor: 10.793

4.  Spectrum of tuberculosis in patients with HIV infection in British Columbia: report of 40 cases.

Authors:  M Korzeniewska-Kosela; J M FitzGerald; S Vedal; E A Allen; M T Schechter; L Lawson; P Phillips; W Black; J S Montaner
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

5.  Directly observed treatment of tuberculosis. We can't afford not to try it.

Authors:  M D Iseman; D L Cohn; J A Sbarbaro
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

6.  A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test.

Authors:  J M Fitzgerald; A Gafni
Journal:  Am Rev Respir Dis       Date:  1990-10

7.  Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity.

Authors:  R Menzies; B Vissandjee
Journal:  Am Rev Respir Dis       Date:  1992-03

8.  An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HIV infection.

Authors:  M Schulzer; J M Fitzgerald; D A Enarson; S Grzybowski
Journal:  Tuber Lung Dis       Date:  1992-02

9.  Detection of Mycobacterium tuberculosis in sputum samples using a polymerase chain reaction.

Authors:  K D Eisenach; M D Sifford; M D Cave; J H Bates; J T Crawford
Journal:  Am Rev Respir Dis       Date:  1991-11

10.  Characterization of a DNA probe for detection of Mycobacterium tuberculosis complex in clinical samples by polymerase chain reaction.

Authors:  M Altamirano; M T Kelly; A Wong; E T Bessuille; W A Black; J A Smith
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

View more
  4 in total

Review 1.  Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions.

Authors:  R E Thomas
Journal:  Can Fam Physician       Date:  1997-05       Impact factor: 3.275

2.  How much does it cost to manage paediatric tuberculosis? One-year experience from The Hospital for Sick Children.

Authors:  C L Main; E Ying; E E Wang
Journal:  Can J Infect Dis       Date:  1998-11

3.  Tuberculosis. A widespread health issue.

Authors:  D Holton
Journal:  Can Fam Physician       Date:  1995-09       Impact factor: 3.275

4.  [Prevalence of positive tuberculin test in a population of patients requiring long-term care in a hospital setting].

Authors:  Y Leduc; S Drapeau; I Samson; R Tremblay; J G Emond
Journal:  Can Fam Physician       Date:  1997-12       Impact factor: 3.275

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.